Cytiva published an article exploring what happens during final UF/DF and how to reduce aggregation risk.
Published
Signal category
Research & Knowledge
Quote
“Our latest article explores what’s happening during final UF/DF - and how to reduce aggregation risk.”
— Darren Small|Cytiva team
Company
Cytiva
We envision a world in which access to life-changing therapies transforms human health.
- Industry
- Biotechnology Research
- Location
- Global, OO
- Company size
- 9,958 employees
Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. We're the provider of leading life science brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman. We are part of Danaher, a global science and technology leader. Along with other Danaher businesses, we accelerate the impact of tomorrow’s science and technology innovation to improve human health. Visit https://www.cytiva.com/privacy to review our privacy policy.